Entera Bio Ltd. (NasdaqCM: ENTX)
Health Care · Biotechnology · IL
$2.68
+0.75% today · +8.5% 1Y
Entera Bio Ltd. (NasdaqCM: ENTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $466.11M and employs 21 people.
Over the last twelve months the share price has gained 8.5%, trading between 0.91 and 4.20.
Tweenvest scores Entera Bio Ltd. across four factors: quality 35/100, value 94/100. Its strongest factor is value.
ENTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $466.11M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- 1.41
- 52-week high
- $4.20
- 52-week low
- $0.91
- Avg volume (3M)
- —
- Shares outstanding
- 173.92M
- Employees
- 21
- Next earnings
- —
About Entera Bio Ltd.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
- ISIN
- IL0011429839
- Founded
- 2009
- Listed since
- Jun 28, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Gongwin Biopharm Holdings Co., Ltd.TPEX: 6617 | $472.24M | NT$126.50 | +6.30% |
| Beijing Leadman Biochemistry Co.,Ltd.SZSE: 300289 | $469.93M | CN¥5.78 | -5.56% |
| Qingdao Vland Biotech INC.SHSE: 603739 | $468.53M | CN¥12.39 | -10.48% |
| Lifecome Biochemistry Co.,Ltd.SZSE: 002868 | $467.33M | CN¥20.12 | -8.96% |
| Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683 | $465.58M | CN¥23.80 | -9.95% |
| Monopar Therapeutics Inc.NasdaqCM: MNPR | $464.95M | $69.27 | -12.27% |
| Ovid Therapeutics Inc.NasdaqCM: OVID | $462.86M | $2.37 | -4.05% |
| Qyuns Therapeutics Co., Ltd.SEHK: 2509 | $455.41M | HK$16.00 | -5.88% |
Figures last refreshed Oct 18, 2026.